aTYR PHARMA INC Long-Term Debt
aTYR PHARMA INC (ATYR) had Long-Term Debt of $2.74 million as of 2019-09-30, per its 10-Q filed 2019-11-14.
Discontinued › Balance Sheet › Liabilities › Liabilities, Noncurrent › Long-Term Debt, Excluding Current Maturities
us-gaap:LongTermDebtNoncurrent · last filed 2020-03-26
- 2019-09-30: Long-term Debt, Excluding Current Maturities $2.74M.
- 2019-06-30: Long-term Debt, Excluding Current Maturities $4.60M.
- 2019-03-31: Long-term Debt, Excluding Current Maturities $6.44M.
- 2018-12-31: Long-term Debt, Excluding Current Maturities $8.26M.
| Period end | Long-term Debt, Excluding Current Maturities |
|---|---|
| 2019-09-30 | $2.74M 10-Q · filed 2019-11-14 |
| 2019-06-30 | $4.60M 10-Q · filed 2019-08-14 |
| 2019-03-31 | $6.44M 10-Q · filed 2019-05-14 |
| 2018-12-31 | $8.26M 10-K · filed 2020-03-26 |
| 2018-09-30 | $10.06M 10-Q · filed 2018-11-14 |
| 2018-06-30 | $11.85M 10-Q · filed 2018-08-14 |
| 2018-03-31 | $12.95M 10-Q · filed 2018-05-15 |
| 2017-12-31 | $14.72M 10-K · filed 2019-03-26 |
| 2017-09-30 | $12.48M 10-Q · filed 2017-11-14 |
| 2017-06-30 | $11.79M 10-Q · filed 2017-08-14 |
| 2017-03-31 | $8.48M 10-Q · filed 2017-05-11 |
| 2016-12-31 | $9.20M 10-K · filed 2018-03-20 |
| 2015-12-31 | $1.78M 10-K · filed 2017-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |